JP2020510659A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020510659A5 JP2020510659A5 JP2019546903A JP2019546903A JP2020510659A5 JP 2020510659 A5 JP2020510659 A5 JP 2020510659A5 JP 2019546903 A JP2019546903 A JP 2019546903A JP 2019546903 A JP2019546903 A JP 2019546903A JP 2020510659 A5 JP2020510659 A5 JP 2020510659A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- cd16a
- acid residues
- binding molecule
- linker
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17158566.4 | 2017-02-28 | ||
| EP17158566 | 2017-02-28 | ||
| EP17174407.1 | 2017-06-02 | ||
| EP17174407 | 2017-06-02 | ||
| PCT/EP2018/054989 WO2018158349A1 (en) | 2017-02-28 | 2018-02-28 | Tandem diabody for cd16a-directed nk-cell engagement |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020510659A JP2020510659A (ja) | 2020-04-09 |
| JP2020510659A5 true JP2020510659A5 (enExample) | 2021-04-01 |
| JP7115758B2 JP7115758B2 (ja) | 2022-08-09 |
Family
ID=61569251
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019546903A Active JP7115758B2 (ja) | 2017-02-28 | 2018-02-28 | Ｃｄ１６ａ指向性ｎｋ細胞エンゲージメント用タンデムダイアボディ |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US11180558B2 (enExample) |
| EP (1) | EP3589655B1 (enExample) |
| JP (1) | JP7115758B2 (enExample) |
| CN (1) | CN110382539B (enExample) |
| AU (1) | AU2018228719B2 (enExample) |
| CA (1) | CA3051062C (enExample) |
| DK (1) | DK3589655T3 (enExample) |
| WO (1) | WO2018158349A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20201346A1 (es) * | 2018-04-13 | 2020-11-25 | Affimed Gmbh | Constructos de fusion de anticuerpos que se acoplan a celulas nk |
| AU2021357841A1 (en) * | 2020-10-08 | 2023-06-15 | Affimed Gmbh | Trispecific binders |
| CN116323671A (zh) * | 2020-11-06 | 2023-06-23 | 安进公司 | 具有增加的选择性的多靶向性双特异性抗原结合分子 |
| CN116745324A (zh) * | 2021-01-27 | 2023-09-12 | 信达生物制药(苏州)有限公司 | 针对cd16a的单域抗体及其用途 |
| CN117580865A (zh) * | 2021-06-29 | 2024-02-20 | 山东先声生物制药有限公司 | Cd16抗体及其应用 |
| KR20240099382A (ko) * | 2021-11-03 | 2024-06-28 | 아피메트 게엠베하 | 이중특이적 cd16a 결합제 |
| MX2024005397A (es) * | 2021-11-03 | 2024-05-23 | Affimed Gmbh | Agentes de union a cd16a biespecificos. |
| CN114262382B (zh) * | 2021-12-20 | 2023-09-19 | 上海恩凯细胞技术有限公司 | 双特异性抗体及其应用 |
| WO2024040194A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
| CN115960234B (zh) * | 2022-10-27 | 2023-12-29 | 合肥天港免疫药物有限公司 | 抗cd16a的抗体及其应用 |
| WO2024131731A1 (zh) | 2022-12-19 | 2024-06-27 | 和铂医药(上海)有限责任公司 | "κ/λ"Fab-Fab串联多特异性结合蛋白及其制备和应用 |
| CN121666232A (zh) | 2023-05-31 | 2026-03-13 | 开普斯坦治疗公司 | 脂质纳米颗粒制剂和组合物 |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| WO2025076127A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025179294A2 (en) | 2024-02-22 | 2025-08-28 | Capstan Therapeutics, Inc. | Immune engineering amplification |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| CN121591895A (zh) * | 2024-08-23 | 2026-03-03 | 安升（上海）医药科技有限公司 | 一种抗CD16a的单域抗体及其应用 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19819846B4 (de) * | 1998-05-05 | 2016-11-24 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Multivalente Antikörper-Konstrukte |
| WO2002066516A2 (en) | 2001-02-20 | 2002-08-29 | Zymogenetics, Inc. | Antibodies that bind both bcma and taci |
| DE60127143T2 (de) * | 2001-11-14 | 2007-11-15 | Affimed Therapeutics Ag | Bispezifische Antikörper gegen CD19 und CD16 und deren Verwendung |
| GB0510790D0 (en) * | 2005-05-26 | 2005-06-29 | Syngenta Crop Protection Ag | Anti-CD16 binding molecules |
| ES2702087T3 (es) * | 2007-06-21 | 2019-02-27 | Macrogenics Inc | Diacuerpos covalentes y sus usos |
| AU2010224160A1 (en) | 2009-03-10 | 2011-09-22 | Biogen Idec Ma Inc. | Anti-BCMA antibodies |
| US20110206672A1 (en) * | 2010-02-25 | 2011-08-25 | Melvyn Little | Antigen-Binding Molecule And Uses Thereof |
| EP2361936B1 (en) * | 2010-02-25 | 2016-04-20 | Affimed GmbH | Antigen-binding molecule and uses thereof |
| SG194176A1 (en) | 2011-05-27 | 2013-12-30 | Glaxo Group Ltd | Bcma (cd269/tnfrsf17) -binding proteins |
| WO2013013700A1 (en) * | 2011-07-22 | 2013-01-31 | Affimed Therapeutics Ag | Multivalent antigen-binding fv molecule |
| TWI679212B (zh) | 2011-11-15 | 2019-12-11 | 美商安進股份有限公司 | 針對ｂｃｍａ之e3以及ｃｄ３的結合分子 |
| EP2914628A1 (en) | 2012-11-01 | 2015-09-09 | Max-Delbrück-Centrum für Molekulare Medizin | An antibody that binds cd269 (bcma) suitable for use in the treatment of plasma cell diseases such as multiple myeloma and autoimmune diseases |
| ES2667420T3 (es) | 2013-02-05 | 2018-05-10 | Engmab Sàrl | Anticuerpos biespecíficos contra cd3epsilon y bcma |
| AR095374A1 (es) | 2013-03-15 | 2015-10-14 | Amgen Res Munich Gmbh | Moléculas de unión para bcma y cd3 |
| SI3030581T1 (sl) * | 2013-08-07 | 2021-07-30 | Affimed Gmbh | Mesta za vezavo na protitelo, ki so specifična za EGFRVIII |
| GB201505305D0 (en) | 2015-03-27 | 2015-05-13 | Immatics Biotechnologies Gmbh | Novel Peptides and combination of peptides for use in immunotherapy against various tumors |
| PT3292153T (pt) * | 2015-05-04 | 2019-11-05 | Affimed Gmbh | Combinação de um anticorpo cd30xcd16a com um anticorpo antagonístico anti-pd-1 para terapia |
| CN105367660B (zh) * | 2015-12-22 | 2018-12-21 | 深圳市北科生物科技有限公司 | 一种抗cd16a抗原和抗muc1抗原的双特异性抗体 |
-
2018
- 2018-02-28 AU AU2018228719A patent/AU2018228719B2/en active Active
- 2018-02-28 WO PCT/EP2018/054989 patent/WO2018158349A1/en not_active Ceased
- 2018-02-28 CN CN201880014655.0A patent/CN110382539B/zh active Active
- 2018-02-28 DK DK18708967.7T patent/DK3589655T3/da active
- 2018-02-28 EP EP18708967.7A patent/EP3589655B1/en active Active
- 2018-02-28 CA CA3051062A patent/CA3051062C/en active Active
- 2018-02-28 JP JP2019546903A patent/JP7115758B2/ja active Active
-
2019
- 2019-07-23 US US16/520,218 patent/US11180558B2/en active Active
-
2021
- 2021-10-26 US US17/510,738 patent/US12264198B2/en active Active